Jackie has 30 years of management experience in the pharmaceutical and biotechnology industries working in business development and senior management/CEO roles with several ASX listed companies including Starpharma, Faulding (now part of Pfizer) and CSL.

Jackie was appointed Chief Executive Officer of ASX listed Starpharma Holdings Ltd in 2006 and under her leadership the company has developed and achieved Australian and international regulatory approval for two novel healthcare products (VivaGel® BV and the VivaGel® antiviral condom) and developed several new and valuable commercial platform applications for Starpharma’s proprietary polymer technology. These include DEP™ for Drug Delivery which was the subject of a multi-product license to AstraZeneca in a deal estimated to yield in excess of $450million for the first product alone. Starpharma now has 3 DEP oncology programs with AstraZeneca.

During her tenure Starpharma has signed commercial deals with leading global companies including Astra Zeneca, Ansell, Lilly, Aspen Pharmacare, GSK, Mundipharma, Okamoto Industries Inc. and Agrium Inc. The company's has also joined the ASX300 index and significantly strengthened its institutional shareholder base, attracting investment from major European, US and Asian institutions.

Jackie holds first class honours degrees in Science and Veterinary Science from Melbourne University. She also has an MBA from the Melbourne Business School where she was the recipient of the prestigious Clemenger Medal. Jackie is also a Graduate of the Australian Institute of Company Directors and in 2016 was elected a Fellow of the Australian Academy of Technology and Engineering (ATSE).

In addition to her role at Starpharma Jackie is a Director of the Melbourne Business School and listed investment company Mirrabooka Investments Ltd. She is also a member the Investment Committee for Mark Carnegie’s Innovation Fund and past member of of the Commonwealth Science Council.

Areas of Expertise